Presenting my project at the SHiMR seminar was a true honour. It provided a great opportunity to reflect on my PhD journey. I want to thank Prof Elisabetta Verderio Edwards, who not only guided and prepared me really well but also never stopped believing in me. @eliverdee
The 2024 #NobelPrize laureates in chemistry Demis Hassabis and John Jumper have successfully utilised artificial intelligence to predict the structure of almost all known proteins.
In 2020, Hassabis and Jumper presented an AI model called AlphaFold2. With its help, they have been able to predict the structure of virtually all the 200 million proteins that researchers have identified. Since their breakthrough, AlphaFold2 has been used by more than two million people from 190 countries. Among a myriad of scientific applications, researchers can now better understand antibiotic resistance and create images of enzymes that can decompose plastic.
Read more about their story: bit.ly/3XI7KK3
Happy to share with you our new study on how h-MSCs promote matrix remodelling by microglia, funded HORIZON2020 PREMSTEM project @premstem, with the collaboration of Rocco Piazza, Pierre Gressens, @eliverdee et al. mdpi.com/2073-4409/13/19/166…@CNRsocial_
Researchers @NottmTrentUni are leading a new study to investigate a non-invasive and targeted treatment of Alzheimer’s, dementia and Parkinson’s.
It is being made possible with more than £1 million from the Eranda Rothschild Foundation.
@NTUSciTechindependent.co.uk/news/scien…
So much talent in the East Midlands at “Matrix and Messengers” (University of Nottingham-NTU) 🙏 today including the EX-Cell lab 😉 @NTUBIOSCIENCES @NTU_Metabolism @NTUNeuro
With profound sadness and sorrow we announce the unexpected passing of our cherished colleague and friend Marina Cretich. Marina exemplified dedication and professionalism, serving as a beacon of inspiration and a cornerstone for us all [...]
Kidney scarring or fibrosis occurs as a consequence of all CKD, but there is no specific treatment for kidney fibrosis. This article describes recent progress behind the discovery and development of a new potential therapy for kidney fibrosis bit.ly/JASN0327
ALT Efficacy of HIPK2 inhibitor against kidney fibrosis. While TGF-β or HIPK2 are key promoters of kidney fibrosis, because of their pleiotropic functions, full blockade of their functions may lead to adverse side effects. As HIPK2 is typically increased in disease settings to potentiate Smad3-mediated transcription, allosteric inhibition of HIPK2-Smad3 interaction by RLA-23174 is sufficient to markedly reduce kidney fibrosis, without incurring potential systemic toxicities associated with TGF-β or HIPK2 inhibition. HIPK2, homeodomain-interacting protein kinase 2; TGF, transforming growth factor.
This is a very special paper to us all. Hope you'll enjoy the reading! ➡️ Addressing Heterogeneity in Direct Analysis of Extracellular Vesicles and Their Analogs by Membrane Sensing Peptides as Pan‐Vesicular Affinity Probes - @LabGori - Advanced Science - onlinelibrary.wiley.com/doi/…
A string of awards ended the #2024TGdisease: Best overall short presentation (60th FEBS anniversary prize), Best presentation for Clarity and Budding Star...but ALL ECRs WERE AMAZING 🤩@FEBSnews
Very grateful to FEBS for the Youth Travel Fund Fellowship and honored to have received an award for my poster! A great way to end my first trip to Italy!